Mineralys Therapeutics EBIT

As of the most recent data (June 2026), MLYS shows a EBIT of $-360M. That compares with $-200M in the prior-year period — down 78.1% year over year. That is below the sector sector average of $-9.6M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLYS's EBIT is now $-360M (was $-200M) — a 78.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Mineralys Therapeutics is outperforming or lagging.

The its sector sector average EBIT is about $-9.6M. Mineralys Therapeutics is at $-360M, which is lower that average. That is roughly 3654.2% below the sector mean. Use the comparison chart on this page to see how MLYS stacks up against individual peers as well.

Tracking MLYS's ebit over time shows whether Mineralys Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-360M That compares with $-200M in the prior-year period — down 78.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Mineralys Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-360M) with ownership activity and broader fundamentals.